A5053810340- Tuberculosis Research and Epidemiology
- Pharmaceutical studies and practices
- Pharmacological Effects and Toxicity Studies
- Immunodeficiency and Autoimmune Disorders
- CAR-T cell therapy research
- HIV-related health complications and treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Immune Cell Function and Interaction
- HIV Research and Treatment
- Antibiotics Pharmacokinetics and Efficacy
- Leprosy Research and Treatment
- Drug Transport and Resistance Mechanisms
- Pneumonia and Respiratory Infections
- Reproductive Health and Contraception
- HIV/AIDS drug development and treatment
- Antimicrobial Resistance in Staphylococcus
- Alcoholism and Thiamine Deficiency
- Viral Infections and Immunology Research
- Heart Failure Treatment and Management
- Antibiotic Resistance in Bacteria
- Viral gastroenteritis research and epidemiology
- Cystic Fibrosis Research Advances
- COVID-19 Clinical Research Studies
- Cardiovascular Function and Risk Factors
- Adolescent and Pediatric Healthcare
University of California, San Francisco
2018-2024
University of Minnesota
2012
Central DuPage Hospital
2009
<p>Selected Cytokine Concentration-Time Profiles for Approved T-Cell Engaging Bispecific Antibodies (T-BiSp)</p>
<p>Overview of CRS Occurrence, Dosing Regimens, and Exposure Metrics for Exposure-Response Analyses T-Cell Engaging Bispecific Antibodies (T-BiSp)</p>
<div>Abstract<p>Cytokine release syndrome (CRS) is a common acute toxicity in T-cell therapies, including T-cell–engaging bispecific antibodies (T-BiSp). Effective CRS management and prevention are crucial T-BiSp development. Required hospitalization for seven of the nine approved need clinical intervention severe cases highlight importance mitigation strategies to reduce health care burden improve patient outcomes. In this review, we discuss emerging evidence on mitigation,...
Objective: This study aimed to evaluate the impact of socioeconomic disparities on allocation second-line treatments among patients with type 2 diabetes (T2D). Materials and Methods: We conducted an observational using real-world data from over 9 million across five University California Health centers. The included who initiated a T2D medication after metformin, hemoglobin A1c (HbA1c) measurements within (+/-) 7 days treatment initiation 2012 through September 2024. Multinomial regression...
The aging HIV population has increased comorbidity burden and consequently non-antiretroviral medication utilization. Many medications have known neurocognitive-adverse effects ("NC-AE medications"). We assessed the cognitive of NC-AE in HIV+ HIV- women.
Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there limited pediatric pharmacokinetic and safety data, especially in young children. We characterize moxifloxacin population pharmacokinetics QT interval prolongation evaluate optimal dosing children with RR-TB.Pharmacokinetic data were pooled from 2 observational studies South African RR-TB routinely treated oral once daily. The Fridericia-corrected (QTcF)-interval characterized NONMEM....
Electronic health records (EHRs) provide meaningful knowledge of drug‐related adverse events (AEs) that are not captured in standard drug development and postmarketing surveillance. Using variables obtained from EHR data the University California San Francisco de‐identified Clinical Data Warehouse, we aimed to evaluate potential machine learning predict two hematological AEs, thrombocytopenia anemia, a cohort patients treated with linezolid for 3 or more days. Features model input were...
Abstract Background Pharmacokinetic data for bedaquiline in children are limited. We described the pharmacokinetics and safety of South African adolescents receiving treatment multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB) routine care. Methods In this observational cohort study, aged 6–17 years at recommended doses as part MDR/RR-TB underwent semi-intensive pharmacokinetic sampling. Bedaquiline M2 metabolite plasma concentrations were quantified, nonlinear mixed-effects modeling...
Rifampicin-resistant tuberculosis (RR-TB) involves treatment with many drugs that can prolong the QT interval; this risk may increase when multiple QT-prolonging are used together. We assessed interval prolongation in children RR-TB receiving one or more drugs. Data were obtained from two prospective observational studies Cape Town, South Africa. Electrocardiograms performed before and after drug administration of clofazimine (CFZ), levofloxacin (LFX), moxifloxacin (MFX), bedaquiline (BDQ),...
Aging in people with HIV is associated increased risk of developing synergistic conditions such as neurocognitive impairment, polypharmacy, and falls. We assessed associations between polypharmacy (use 5 or more non-ART medications), use adverse effects (NCAE) medications, odds falls women (WWH) without (HIV-).Self-reported medication data were contributed semiannually by 1872 (1315 WWH 557 HIV-) Women's Interagency Study participants 2014 2016. Polypharmacy NCAE evaluated separately jointly...
Background: Neurocognitive impairment is a frequent and often disabling comorbidity of HIV infection. In addition to antiretroviral therapies, individuals with infection may commonly use nonantiretroviral medications that are known cause neurocognitive adverse effects (NC-AE). The contribution NC-AE rarely considered in the context could explain part variability performance among HIV. Setting: Women's Interagency Study, prospective, multisite, observational study US women without Methods:...
Moxifloxacin (MOX) is used as a first-choice drug to treat multidrug-resistant tuberculosis (MDR-TB); however, evidence-based dosing optimization should be strengthened by integrative analysis. The primary goal of this study was evaluate MOX efficacy and toxicity using model-based approaches in MDR-TB patients. In total, 113 patients from 5 different clinical trials were analyzed for the development population pharmacokinetics (PK) model. A final PK model merged with previously developed...
Rifapentine has facilitated treatment shortening for latent tuberculosis infection (LTBI) in combination with isoniazid once weekly 3 months (3HP) or daily 1 month (1HP). Our objective was to determine the optimal rifapentine dose a 6-week monotherapy regimen (6wP) and predict clinical efficacy. pharmacokinetics were simulated mice humans. Mouse lung CFU data used characterize exposure-response relationships of 1HP, 3HP, 6wP translated A 600-mg delivered greater cumulative exposure than 1HP...
Abstract Clinical trials of pharmacologic treatments coronavirus disease 2019 (COVID-19) are being rapidly designed and implemented in adults. Children often not considered during development novel for infectious diseases until very late. Although children appear to have a lower risk compared with adults severe COVID-19 disease, substantial number globally will benefit from treatments. It be reasonable extrapolate efficacy most adult children. Pediatric should focus on characterizing...
There is an increased interest in utilizing real-world data (RWD) for pharmaceutical research and regulatory decision-making. The development use of pediatric medicines could benefit greatly from studies given nearly half drugs prescribed to children are “off-label”, meaning there a lack pediatric-specific evidence controlled trials, while abundance routine clinical practice. Currently, the data, such as electronic health records, lacking research, especially within infectious diseases....